End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.46 CNY | +0.17% | -1.89% | -41.64% |
Jun. 06 | Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists | RE |
Jun. 01 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.64% | 16.43B | A- | ||
+18.34% | 125B | B+ | ||
+15.06% | 108B | B+ | ||
-6.39% | 23.64B | B+ | ||
+2.39% | 22.39B | B | ||
-12.11% | 17.78B | A- | ||
-12.07% | 16.34B | B | ||
+1.05% | 13.56B | C+ | ||
+25.87% | 11.59B | C+ | ||
+99.65% | 9.66B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603259 Stock
- Ratings WuXi AppTec Co., Ltd.